<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137890</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA027065</org_study_id>
    <secondary_id>R01DA027065</secondary_id>
    <nct_id>NCT01137890</nct_id>
  </id_info>
  <brief_title>Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse</brief_title>
  <official_title>Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a residential pilot trial to evaluate the pharmacodynamic interaction between
      zonisamide and cocaine, with the goal of evaluating zonisamide's potential for the treatment
      of cocaine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a residential pilot trial to evaluate the effect of zonisamide (ZNS) on cocaine
      reinforcement, craving and relapse. Cocaine addiction remains a major social and medical
      problem that imposes a significant burden on our society, as more than a half million cocaine
      dependent individuals are seeking treatment every year. Medications that act to antagonize
      the glutamate system and/or increase the GABA-system are new targets in the search towards
      effective cocaine treatment. ZNS is part of a new line of antiepileptic agents that act both
      as glutamate antagonists and to enhance the Gamma-AminoButyric acid (GABA) system.
      Topiramate, a similar agent, showed a positive signal in a pilot trial for cocaine
      dependence. ZNS has the advantages of a longer half-life requiring only once a day dosing
      and, being better tolerated, it requires a shorter induction phase and can be administered at
      higher doses. We hypothesize that ZNS in moderate to high doses will attenuate the central
      effect of cocaine and improve the neural perturbations resulting from cocaine use, thus
      decreasing cocaine craving. Healthy, adult cocaine dependent volunteers will be enrolled on
      our residential unit for 44 days for this double-blind within subject study. The
      pharmacodynamic interactions between ZNS and cocaine will be measured in cocaine
      self-administration procedure offering alternative reinforcers with monetary values. Cocaine
      reinforcing effect will be evaluated over a range of doses, and subjective and objective
      outcomes on mood and behavior will be collected. In addition, the effect of ZNS on ad-lib
      smoking will be studied on the days when no other procedure interferes with smoking
      behaviors. Neurocognitive and psychomotor effects of ZNS treatment will also be studied with
      an extensive test battery on the day of the week when no cocaine is administered. This study
      will explore the potential therapeutic effect of ZNS for the treatment of cocaine dependence
      while providing necessary safety assessments required for possible future outpatient clinical
      trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Questionnaire (VAQ) Score</measure>
    <time_frame>Weeks 1-5; mean of weeks 1, 3 and 5 reported</time_frame>
    <description>VAQ measures the change in effect after dose administration. Participants rate 6 items (&quot;Any Drug Effect&quot;, &quot;Rush&quot;, &quot;Good Effects&quot;, &quot;Bad Effects&quot;, &quot;Liking&quot;, &amp; &quot;Desire for Cocaine&quot;) by pointing an arrow along a 100-point line anchored at either end with &quot;none&quot; (0) &amp; &quot;extremely&quot; (100). Each participant's score is equal to the sum of all 6 ratings, &amp; the mean of all participant's scores is reported across each condition. The VAQ is only administered to subjects in the zonisamide (Zon) condition (n=8). Repeated within-subject measures ANOVA performed to observe the main effects of Zon dose (0, 300, &amp; 600mg) &amp; cocaine dose (1, 20, &amp; 40mg), &amp; their interaction. All 8 subjects who received Zon completed both 300mg &amp; 600mg doses. Assessments obtained on Week 1 (0mg Zon), Week 3 (300mg Zon), &amp; Week 5 (600mg Zon), in which all 3 cocaine were co-administered at these times. Cocaine not administered (only Zon) during Weeks 2 &amp; 4, thus no measures taken at these times</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Choice Measures</measure>
    <time_frame>Weeks 1-5, mean of weeks 1, 3 and 5 reported</time_frame>
    <description>In each condition of cocaine-zonisamide dose, participants were asked to choose whether they would rather have a repeated cocaine dose (same dose as most recent administration) or cash of varying monetary value. The mean number of cocaine choices across each drug condition are reported. This measure only included participants in the zonisamide (Zon) condition (n=8), with each arm representing variation in co-administration of cocaine-Zon.
Repeated within-subject measures ANOVA performed to observe the main effects of zonisamide dose (0, 300, and 600mg) and cocaine dose (1, 20, and 40mg), and their interaction. Only participants who received the active zonisamide medication (n=8) were included in this portion of the analysis.
During self-administration sessions are every 15 min over 1hr45min period. Assessment on Weeks 1 (0mg Zon), 3 (300mg Zon), 5 (600mg Zon), in which varying cocaine doses co-administered. Cocaine not administered (only Zon) during Weeks 2 &amp; 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine Craving</measure>
    <time_frame>Day 1-39</time_frame>
    <description>Cocaine craving measured by Cocaine Selectivity Severity Assessment (CSSA). The CSSA is a reliable and valid tool to measure cocaine withdrawal severity within a 24 hr period, and has been shown to predict treatment response in a treatment setting. Participants are asked to rate 18-items on a Likert scale 0-7, with composite scores ranging 0-126 and higher numbers indicative of more severe withdrawal. Mean scores on CSSA across 39-day time period are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Value Questionnaire</measure>
    <time_frame>Weeks 1-5; mean of weeks 1, 3 and 5 reported</time_frame>
    <description>Street Value of Sampled Dose. After co-administration of cocaine-zonisamide, participants were asked to hypothetically estimate the value of the drug they received, if they were to purchase it on the street. The mean value (dollars) across all drug conditions is reported here.
Repeated within-subject measures ANOVA performed to observe the main effects of zonisamide dose (0, 300, and 600mg) and cocaine dose (0, 20, and 40mg), and their interaction. Only participants who received the active zonisamide medication (n=8) were included in this portion of the analysis. Additionally, all 8 subjects who received zonisamide completed both 300mg and 600mg doses.
Within-subject repeated interval during self-administration sessions. Cocaine not administered (only Zon) during Weeks 2 &amp; 4, thus no measures taken at these times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered blind capsules containing either placebo or zonisamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants administered only placebo capsules containing lactose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>Eight capsules administered daily in split doses at 22:00 and 09:00.</description>
    <arm_group_label>Zonisamide</arm_group_label>
    <other_name>Zonegran,</other_name>
    <other_name>CAS 68291-97-4,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsules administered in split doses at 22:00 and 09:00.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine Hydrochloride</intervention_name>
    <description>Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.</description>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>CAS 50-36-2</other_name>
    <other_name>methylbenzoylecgonine</other_name>
    <other_name>benzoylmethylecgonine</other_name>
    <other_name>C17H21NO4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurocognitive and Performance Battery</intervention_name>
    <description>Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.</description>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Assessments</intervention_name>
    <description>Participants answer questions about smoking and smoking behaviors are monitored.</description>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 21 years old, not older than 45 years.

          -  Evidence of cocaine dependence.

          -  Not seeking treatment for cocaine abuse.

          -  Able and willing to be restricted to our unit for 6-7 weeks.

          -  Able to answer frequent questionnaires reliably and consistently.

          -  Smoker.

        Exclusion Criteria:

          -  Allergy to Sulfonamide drugs (e.g. topiramate, zonisamide,
             sulfamethoxazole/trimethoprim).

          -  Diabetes, respiratory insufficiency, renal tubular acidosis or renal insufficiency,
             heart failure, liver insufficiency, chronic diarrhea, other chronic diseases
             predisposing to acidosis.

          -  Renal insufficiency defined as serum creatine &gt; 1.30 mg/DL for males or &gt; 1.03 mg/DL
             for females.

          -  History of nephrolithiasis, unexplained hematuria on screening urinalysis.

          -  History of head injury (with loss of consciousness longer than a few minutes).

          -  History of seizure, or use of antiepileptic medications.

          -  HIV positive individuals who meet AIDS by Centers for Disease Control (CDC) criteria
             or are on antiretroviral medications.

          -  BMI &lt; 19 or BMI &gt; 34.

          -  Total cholesterol &gt; 240mg%.

          -  Serous psychiatric illness with psychosis, dementia.

          -  Glaucoma, family history of glaucoma, one-sided blindness.

          -  For female participants: being pregnant, lactating or not using an effective method of
             contraception.

          -  Physical dependence on any drug other than cocaine, nicotine, or caffeine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie Umbricht, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>September 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2017</results_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>addiction</keyword>
  <keyword>drug dependence</keyword>
  <keyword>anticonvulsant</keyword>
  <keyword>zonisamide</keyword>
  <keyword>drug self-administration</keyword>
  <keyword>nicotine withdrawal</keyword>
  <keyword>neurocognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zonisamide</title>
          <description>Participants administered blind capsules containing either placebo or zonisamide.
Zonisamide: Eight capsules administered daily in split doses at 22:00 and 09:00.
Cocaine Hydrochloride: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
Neurocognitive and Performance Battery: Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
Smoking Assessments: Participants answer questions about smoking and smoking behaviors are monitored.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants administered only placebo capsules containing lactose.
Placebo: capsules administered in split doses at 22:00 and 09:00.
Cocaine Hydrochloride: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
Neurocognitive and Performance Battery: Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
Smoking Assessments: Participants answer questions about smoking and smoking behaviors are monitored.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zonisamide</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="5.6"/>
                    <measurement group_id="B2" value="38.2" spread="4.1"/>
                    <measurement group_id="B3" value="38.7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Questionnaire (VAQ) Score</title>
        <description>VAQ measures the change in effect after dose administration. Participants rate 6 items (“Any Drug Effect”, “Rush”, “Good Effects”, “Bad Effects”, “Liking”, &amp; “Desire for Cocaine”) by pointing an arrow along a 100-point line anchored at either end with “none” (0) &amp; “extremely” (100). Each participant’s score is equal to the sum of all 6 ratings, &amp; the mean of all participant’s scores is reported across each condition. The VAQ is only administered to subjects in the zonisamide (Zon) condition (n=8). Repeated within-subject measures ANOVA performed to observe the main effects of Zon dose (0, 300, &amp; 600mg) &amp; cocaine dose (1, 20, &amp; 40mg), &amp; their interaction. All 8 subjects who received Zon completed both 300mg &amp; 600mg doses. Assessments obtained on Week 1 (0mg Zon), Week 3 (300mg Zon), &amp; Week 5 (600mg Zon), in which all 3 cocaine were co-administered at these times. Cocaine not administered (only Zon) during Weeks 2 &amp; 4, thus no measures taken at these times</description>
        <time_frame>Weeks 1-5; mean of weeks 1, 3 and 5 reported</time_frame>
        <population>Because we are interested in how co-administered of cocaine-Zon affects this measure, only Zon participants are included (n=8). Each participant receives varying doses of Zon (0, 300, 600mg) at weeks 1, 2-3, 4-5, respectively. After getting used to each Zon dose, they are co-administered all 3 cocaine doses (1, 20, 40mg) during Weeks 1, 3, and 5</population>
        <group_list>
          <group group_id="O1">
            <title>1mg-0mg</title>
            <description>1mg cocaine - 0mg zonisamide
Both doses are expected to be inactive, thus this arm is viewed as Placebo</description>
          </group>
          <group group_id="O2">
            <title>1mg-300mg</title>
            <description>1mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O3">
            <title>1mg-600mg</title>
            <description>1mg cocaine - 600mg zonisamide</description>
          </group>
          <group group_id="O4">
            <title>20mg-0mg</title>
            <description>20mg cocaine - 0mg zonisamide</description>
          </group>
          <group group_id="O5">
            <title>20mg-300mg</title>
            <description>20mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O6">
            <title>20mg-600mg</title>
            <description>20mg cocaine - 600mg zonisamide</description>
          </group>
          <group group_id="O7">
            <title>40mg-0mg</title>
            <description>40mg cocaine - 0mg zonisamide</description>
          </group>
          <group group_id="O8">
            <title>40mg-300mg</title>
            <description>40mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O9">
            <title>40mg-600mg</title>
            <description>40mg cocaine - 600mg zonisamide</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Questionnaire (VAQ) Score</title>
          <description>VAQ measures the change in effect after dose administration. Participants rate 6 items (“Any Drug Effect”, “Rush”, “Good Effects”, “Bad Effects”, “Liking”, &amp; “Desire for Cocaine”) by pointing an arrow along a 100-point line anchored at either end with “none” (0) &amp; “extremely” (100). Each participant’s score is equal to the sum of all 6 ratings, &amp; the mean of all participant’s scores is reported across each condition. The VAQ is only administered to subjects in the zonisamide (Zon) condition (n=8). Repeated within-subject measures ANOVA performed to observe the main effects of Zon dose (0, 300, &amp; 600mg) &amp; cocaine dose (1, 20, &amp; 40mg), &amp; their interaction. All 8 subjects who received Zon completed both 300mg &amp; 600mg doses. Assessments obtained on Week 1 (0mg Zon), Week 3 (300mg Zon), &amp; Week 5 (600mg Zon), in which all 3 cocaine were co-administered at these times. Cocaine not administered (only Zon) during Weeks 2 &amp; 4, thus no measures taken at these times</description>
          <population>Because we are interested in how co-administered of cocaine-Zon affects this measure, only Zon participants are included (n=8). Each participant receives varying doses of Zon (0, 300, 600mg) at weeks 1, 2-3, 4-5, respectively. After getting used to each Zon dose, they are co-administered all 3 cocaine doses (1, 20, 40mg) during Weeks 1, 3, and 5</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.74"/>
                    <measurement group_id="O2" value="3.75" spread="6.41"/>
                    <measurement group_id="O3" value="0.38" spread="0.74"/>
                    <measurement group_id="O4" value="40.63" spread="24.37"/>
                    <measurement group_id="O5" value="32.63" spread="14.78"/>
                    <measurement group_id="O6" value="30.00" spread="27.88"/>
                    <measurement group_id="O7" value="37.38" spread="21.84"/>
                    <measurement group_id="O8" value="29.75" spread="16.52"/>
                    <measurement group_id="O9" value="37.25" spread="25.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>p-value was calculated as less than 0.01. Note: this is not an attempt to indicate a threshold</p_value_desc>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Coc dose</param_type>
            <param_value>24.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Cocaine dose on VAQ score</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Zon dose</param_type>
            <param_value>0.34</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Zonisamide dose on VAQ score</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Coc x Zon</param_type>
            <param_value>0.66</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Cocaine x Zonisamide interaction on VAQ scores</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Behavioral Choice Measures</title>
        <description>In each condition of cocaine-zonisamide dose, participants were asked to choose whether they would rather have a repeated cocaine dose (same dose as most recent administration) or cash of varying monetary value. The mean number of cocaine choices across each drug condition are reported. This measure only included participants in the zonisamide (Zon) condition (n=8), with each arm representing variation in co-administration of cocaine-Zon.
Repeated within-subject measures ANOVA performed to observe the main effects of zonisamide dose (0, 300, and 600mg) and cocaine dose (1, 20, and 40mg), and their interaction. Only participants who received the active zonisamide medication (n=8) were included in this portion of the analysis.
During self-administration sessions are every 15 min over 1hr45min period. Assessment on Weeks 1 (0mg Zon), 3 (300mg Zon), 5 (600mg Zon), in which varying cocaine doses co-administered. Cocaine not administered (only Zon) during Weeks 2 &amp; 4</description>
        <time_frame>Weeks 1-5, mean of weeks 1, 3 and 5 reported</time_frame>
        <population>Because we are interested in how co-administered of cocaine-Zon affects this measure, only Zon participants are included (n=8). Each participant receives varying doses of Zon (0, 300, 600mg) at weeks 1, 2-3, 4-5, respectively. After getting used to each Zon dose, they are co-administered all 3 cocaine doses (1, 20, 40mg) during Weeks 1, 3, and 5</population>
        <group_list>
          <group group_id="O1">
            <title>1mg-0mg</title>
            <description>1mg cocaine - 0mg zonisamide
Both doses are expected to be inactive, thus this arm is viewed as Placebo</description>
          </group>
          <group group_id="O2">
            <title>1mg-300mg</title>
            <description>1mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O3">
            <title>1mg-600mg</title>
            <description>1mg cocaine - 600mg zonisamide</description>
          </group>
          <group group_id="O4">
            <title>20mg-0mg</title>
            <description>20mg cocaine - 0mg zonisamide</description>
          </group>
          <group group_id="O5">
            <title>20mg-300mg</title>
            <description>20mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O6">
            <title>20mg-600mg</title>
            <description>20mg cocaine - 600mg zonisamide</description>
          </group>
          <group group_id="O7">
            <title>40mg-0mg</title>
            <description>40mg cocaine - 0mg zonisamide</description>
          </group>
          <group group_id="O8">
            <title>40mg-300mg</title>
            <description>40mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O9">
            <title>40mg-600mg</title>
            <description>40mg cocaine - 600mg zonisamide</description>
          </group>
        </group_list>
        <measure>
          <title>Behavioral Choice Measures</title>
          <description>In each condition of cocaine-zonisamide dose, participants were asked to choose whether they would rather have a repeated cocaine dose (same dose as most recent administration) or cash of varying monetary value. The mean number of cocaine choices across each drug condition are reported. This measure only included participants in the zonisamide (Zon) condition (n=8), with each arm representing variation in co-administration of cocaine-Zon.
Repeated within-subject measures ANOVA performed to observe the main effects of zonisamide dose (0, 300, and 600mg) and cocaine dose (1, 20, and 40mg), and their interaction. Only participants who received the active zonisamide medication (n=8) were included in this portion of the analysis.
During self-administration sessions are every 15 min over 1hr45min period. Assessment on Weeks 1 (0mg Zon), 3 (300mg Zon), 5 (600mg Zon), in which varying cocaine doses co-administered. Cocaine not administered (only Zon) during Weeks 2 &amp; 4</description>
          <population>Because we are interested in how co-administered of cocaine-Zon affects this measure, only Zon participants are included (n=8). Each participant receives varying doses of Zon (0, 300, 600mg) at weeks 1, 2-3, 4-5, respectively. After getting used to each Zon dose, they are co-administered all 3 cocaine doses (1, 20, 40mg) during Weeks 1, 3, and 5</population>
          <units>number of cocaine choices</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.25" spread="0.71"/>
                    <measurement group_id="O4" value="2" spread="2.67"/>
                    <measurement group_id="O5" value="2.38" spread="2.33"/>
                    <measurement group_id="O6" value="2.25" spread="2.05"/>
                    <measurement group_id="O7" value="3.5" spread="2.93"/>
                    <measurement group_id="O8" value="3" spread="2.2"/>
                    <measurement group_id="O9" value="3.38" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>p-value was calculated as less than 0.01. Note: this is not an attempt to indicate a threshold</p_value_desc>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Coc dose</param_type>
            <param_value>9.91</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Cocaine dose on Behavioral Choice measure</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Zon dose</param_type>
            <param_value>0.07</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Zonisamide dose on Behavioral Choice measure</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Coc x Zon</param_type>
            <param_value>0.24</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Cocaine dose x Zonisamide dose interaction on Behavioral Choice measure</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Craving</title>
        <description>Cocaine craving measured by Cocaine Selectivity Severity Assessment (CSSA). The CSSA is a reliable and valid tool to measure cocaine withdrawal severity within a 24 hr period, and has been shown to predict treatment response in a treatment setting. Participants are asked to rate 18-items on a Likert scale 0-7, with composite scores ranging 0-126 and higher numbers indicative of more severe withdrawal. Mean scores on CSSA across 39-day time period are reported.</description>
        <time_frame>Day 1-39</time_frame>
        <population>Includes all participants analyzed (n=12; 8 zonisamide, 4 placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
          </group>
          <group group_id="O2">
            <title>Day 2</title>
          </group>
          <group group_id="O3">
            <title>Day 3</title>
          </group>
          <group group_id="O4">
            <title>Day 4</title>
          </group>
          <group group_id="O5">
            <title>Day 5</title>
          </group>
          <group group_id="O6">
            <title>Day 6</title>
          </group>
          <group group_id="O7">
            <title>Day 7</title>
          </group>
          <group group_id="O8">
            <title>Day 8</title>
          </group>
          <group group_id="O9">
            <title>Day 9</title>
          </group>
          <group group_id="O10">
            <title>Day 10</title>
          </group>
          <group group_id="O11">
            <title>Day 11</title>
          </group>
          <group group_id="O12">
            <title>Day 12</title>
          </group>
          <group group_id="O13">
            <title>Day 13</title>
          </group>
          <group group_id="O14">
            <title>Day 14</title>
          </group>
          <group group_id="O15">
            <title>Day 15</title>
          </group>
          <group group_id="O16">
            <title>Day 16</title>
          </group>
          <group group_id="O17">
            <title>Day 17</title>
          </group>
          <group group_id="O18">
            <title>Day 18</title>
          </group>
          <group group_id="O19">
            <title>Day 19</title>
          </group>
          <group group_id="O20">
            <title>Day 20</title>
          </group>
          <group group_id="O21">
            <title>Day 21</title>
          </group>
          <group group_id="O22">
            <title>Day 22</title>
          </group>
          <group group_id="O23">
            <title>Day 23</title>
          </group>
          <group group_id="O24">
            <title>Day 24</title>
          </group>
          <group group_id="O25">
            <title>Day 25</title>
          </group>
          <group group_id="O26">
            <title>Day 26</title>
          </group>
          <group group_id="O27">
            <title>Day 27</title>
          </group>
          <group group_id="O28">
            <title>Day 28</title>
          </group>
          <group group_id="O29">
            <title>Day 29</title>
          </group>
          <group group_id="O30">
            <title>Day 30</title>
          </group>
          <group group_id="O31">
            <title>Day 31</title>
          </group>
          <group group_id="O32">
            <title>Day 32</title>
          </group>
          <group group_id="O33">
            <title>Day 33</title>
          </group>
          <group group_id="O34">
            <title>Day 34</title>
          </group>
          <group group_id="O35">
            <title>Day 35</title>
          </group>
          <group group_id="O36">
            <title>Day 36</title>
          </group>
          <group group_id="O37">
            <title>Day 37</title>
          </group>
          <group group_id="O38">
            <title>Day 38</title>
          </group>
          <group group_id="O39">
            <title>Day 39</title>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving</title>
          <description>Cocaine craving measured by Cocaine Selectivity Severity Assessment (CSSA). The CSSA is a reliable and valid tool to measure cocaine withdrawal severity within a 24 hr period, and has been shown to predict treatment response in a treatment setting. Participants are asked to rate 18-items on a Likert scale 0-7, with composite scores ranging 0-126 and higher numbers indicative of more severe withdrawal. Mean scores on CSSA across 39-day time period are reported.</description>
          <population>Includes all participants analyzed (n=12; 8 zonisamide, 4 placebo)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="12"/>
                <count group_id="O14" value="12"/>
                <count group_id="O15" value="12"/>
                <count group_id="O16" value="12"/>
                <count group_id="O17" value="12"/>
                <count group_id="O18" value="12"/>
                <count group_id="O19" value="12"/>
                <count group_id="O20" value="12"/>
                <count group_id="O21" value="12"/>
                <count group_id="O22" value="12"/>
                <count group_id="O23" value="12"/>
                <count group_id="O24" value="12"/>
                <count group_id="O25" value="12"/>
                <count group_id="O26" value="12"/>
                <count group_id="O27" value="12"/>
                <count group_id="O28" value="12"/>
                <count group_id="O29" value="12"/>
                <count group_id="O30" value="12"/>
                <count group_id="O31" value="12"/>
                <count group_id="O32" value="12"/>
                <count group_id="O33" value="12"/>
                <count group_id="O34" value="12"/>
                <count group_id="O35" value="12"/>
                <count group_id="O36" value="12"/>
                <count group_id="O37" value="12"/>
                <count group_id="O38" value="12"/>
                <count group_id="O39" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Zonisamide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.88" spread="10.25"/>
                    <measurement group_id="O2" value="27.25" spread="15.29"/>
                    <measurement group_id="O3" value="25" spread="14.32"/>
                    <measurement group_id="O4" value="19.13" spread="8.63"/>
                    <measurement group_id="O5" value="17.88" spread="11.51"/>
                    <measurement group_id="O6" value="13.5" spread="8"/>
                    <measurement group_id="O7" value="12.75" spread="11.21"/>
                    <measurement group_id="O8" value="12.13" spread="9.85"/>
                    <measurement group_id="O9" value="13.75" spread="10.93"/>
                    <measurement group_id="O10" value="9.63" spread="8.99"/>
                    <measurement group_id="O11" value="11.75" spread="9.18"/>
                    <measurement group_id="O12" value="14.25" spread="11.41"/>
                    <measurement group_id="O13" value="12.38" spread="10.86"/>
                    <measurement group_id="O14" value="23.63" spread="31.01"/>
                    <measurement group_id="O15" value="26.75" spread="39.46"/>
                    <measurement group_id="O16" value="24.88" spread="39.41"/>
                    <measurement group_id="O17" value="25.38" spread="38.93"/>
                    <measurement group_id="O18" value="24.13" spread="39.47"/>
                    <measurement group_id="O19" value="25.13" spread="39.67"/>
                    <measurement group_id="O20" value="12.75" spread="12.74"/>
                    <measurement group_id="O21" value="25.5" spread="29.82"/>
                    <measurement group_id="O22" value="15.25" spread="14.27"/>
                    <measurement group_id="O23" value="16.88" spread="12.05"/>
                    <measurement group_id="O24" value="13.88" spread="13.07"/>
                    <measurement group_id="O25" value="8.25" spread="9.41"/>
                    <measurement group_id="O26" value="10.25" spread="11"/>
                    <measurement group_id="O27" value="10.75" spread="10.17"/>
                    <measurement group_id="O28" value="7.63" spread="9.78"/>
                    <measurement group_id="O29" value="7.63" spread="10.82"/>
                    <measurement group_id="O30" value="6.57" spread="10.13"/>
                    <measurement group_id="O31" value="9.50" spread="9.09"/>
                    <measurement group_id="O32" value="11.25" spread="12.90"/>
                    <measurement group_id="O33" value="8.5" spread="10.43"/>
                    <measurement group_id="O34" value="13.5" spread="11.49"/>
                    <measurement group_id="O35" value="21.38" spread="17.74"/>
                    <measurement group_id="O36" value="8.13" spread="11.76"/>
                    <measurement group_id="O37" value="23.25" spread="35.25"/>
                    <measurement group_id="O38" value="8.25" spread="11.99"/>
                    <measurement group_id="O39" value="19.25" spread="27.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.75" spread="11"/>
                    <measurement group_id="O2" value="41" spread="20.54"/>
                    <measurement group_id="O3" value="30.25" spread="23.49"/>
                    <measurement group_id="O4" value="28.25" spread="15.73"/>
                    <measurement group_id="O5" value="28.25" spread="14.57"/>
                    <measurement group_id="O6" value="26.5" spread="9.32"/>
                    <measurement group_id="O7" value="29.5" spread="6.35"/>
                    <measurement group_id="O8" value="27.25" spread="11.87"/>
                    <measurement group_id="O9" value="28.5" spread="13.82"/>
                    <measurement group_id="O10" value="19" spread="9.93"/>
                    <measurement group_id="O11" value="25.33" spread="5.85"/>
                    <measurement group_id="O12" value="25.25" spread="15.6"/>
                    <measurement group_id="O13" value="22.75" spread="5.12"/>
                    <measurement group_id="O14" value="22.75" spread="9.74"/>
                    <measurement group_id="O15" value="24.75" spread="14.5"/>
                    <measurement group_id="O16" value="19.25" spread="5.25"/>
                    <measurement group_id="O17" value="24.00" spread="11.53"/>
                    <measurement group_id="O18" value="22.5" spread="12.36"/>
                    <measurement group_id="O19" value="24.5" spread="15.86"/>
                    <measurement group_id="O20" value="26" spread="15.490"/>
                    <measurement group_id="O21" value="25.5" spread="18.21"/>
                    <measurement group_id="O22" value="23" spread="15.09"/>
                    <measurement group_id="O23" value="18" spread="9.17"/>
                    <measurement group_id="O24" value="19" spread="0"/>
                    <measurement group_id="O25" value="15.5" spread="0.70"/>
                    <measurement group_id="O26" value="16." spread="2.83"/>
                    <measurement group_id="O27" value="14.5" spread="2.12"/>
                    <measurement group_id="O28" value="16.5" spread="3.53"/>
                    <measurement group_id="O29" value="24" spread="0"/>
                    <measurement group_id="O30" value="16.5" spread="0.71"/>
                    <measurement group_id="O31" value="16.5" spread="0.71"/>
                    <measurement group_id="O32" value="19.5" spread="4.95"/>
                    <measurement group_id="O33" value="18." spread="2.83"/>
                    <measurement group_id="O34" value="17." spread="1.41"/>
                    <measurement group_id="O35" value="19." spread="7.07"/>
                    <measurement group_id="O36" value="16" spread="0"/>
                    <measurement group_id="O37" value="19" spread="4.24"/>
                    <measurement group_id="O38" value="20" spread="4.24"/>
                    <measurement group_id="O39" value="16.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
              <group_id>O21</group_id>
              <group_id>O22</group_id>
              <group_id>O23</group_id>
              <group_id>O24</group_id>
              <group_id>O25</group_id>
              <group_id>O26</group_id>
              <group_id>O27</group_id>
              <group_id>O28</group_id>
              <group_id>O29</group_id>
              <group_id>O30</group_id>
              <group_id>O31</group_id>
              <group_id>O32</group_id>
              <group_id>O33</group_id>
              <group_id>O34</group_id>
              <group_id>O35</group_id>
              <group_id>O36</group_id>
              <group_id>O37</group_id>
              <group_id>O38</group_id>
              <group_id>O39</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <p_value_desc>Group (Zonisamide vs Placebo)</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>t-value for main effect of Group</param_type>
            <param_value>1.51</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
              <group_id>O21</group_id>
              <group_id>O22</group_id>
              <group_id>O23</group_id>
              <group_id>O24</group_id>
              <group_id>O25</group_id>
              <group_id>O26</group_id>
              <group_id>O27</group_id>
              <group_id>O28</group_id>
              <group_id>O29</group_id>
              <group_id>O30</group_id>
              <group_id>O31</group_id>
              <group_id>O32</group_id>
              <group_id>O33</group_id>
              <group_id>O34</group_id>
              <group_id>O35</group_id>
              <group_id>O36</group_id>
              <group_id>O37</group_id>
              <group_id>O38</group_id>
              <group_id>O39</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day (Day 1-39)</non_inferiority_desc>
            <p_value>0.0015</p_value>
            <method>t-test, 2 sided</method>
            <param_type>t-value for main effect of Day</param_type>
            <param_value>-3.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
              <group_id>O16</group_id>
              <group_id>O17</group_id>
              <group_id>O18</group_id>
              <group_id>O19</group_id>
              <group_id>O20</group_id>
              <group_id>O21</group_id>
              <group_id>O22</group_id>
              <group_id>O23</group_id>
              <group_id>O24</group_id>
              <group_id>O25</group_id>
              <group_id>O26</group_id>
              <group_id>O27</group_id>
              <group_id>O28</group_id>
              <group_id>O29</group_id>
              <group_id>O30</group_id>
              <group_id>O31</group_id>
              <group_id>O32</group_id>
              <group_id>O33</group_id>
              <group_id>O34</group_id>
              <group_id>O35</group_id>
              <group_id>O36</group_id>
              <group_id>O37</group_id>
              <group_id>O38</group_id>
              <group_id>O39</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Group*Day interaction</non_inferiority_desc>
            <p_value>0.10</p_value>
            <method>t-test, 2 sided</method>
            <param_type>t value for Group x Day interaction</param_type>
            <param_value>-1.63</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Value Questionnaire</title>
        <description>Street Value of Sampled Dose. After co-administration of cocaine-zonisamide, participants were asked to hypothetically estimate the value of the drug they received, if they were to purchase it on the street. The mean value (dollars) across all drug conditions is reported here.
Repeated within-subject measures ANOVA performed to observe the main effects of zonisamide dose (0, 300, and 600mg) and cocaine dose (0, 20, and 40mg), and their interaction. Only participants who received the active zonisamide medication (n=8) were included in this portion of the analysis. Additionally, all 8 subjects who received zonisamide completed both 300mg and 600mg doses.
Within-subject repeated interval during self-administration sessions. Cocaine not administered (only Zon) during Weeks 2 &amp; 4, thus no measures taken at these times</description>
        <time_frame>Weeks 1-5; mean of weeks 1, 3 and 5 reported</time_frame>
        <population>Because we are interested in how co-administration cocaine-zon affects this measure, only zon participants are included (n=8). Each participant receives varying doses of zon (0, 300, 600mg) at weeks 1, 2-3, 4-5, respectively. After getting used to each zon dose, they are co-administered all 3 cocaine doses (1, 20, 40mg) during Weeks 1, 3, and 5</population>
        <group_list>
          <group group_id="O1">
            <title>1mg-0mg</title>
            <description>1mg cocaine - 0mg zonisamide
Both doses are expected to be inactive, thus this arm is viewed as Placebo</description>
          </group>
          <group group_id="O2">
            <title>1mg-300mg</title>
            <description>1mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O3">
            <title>1mg-600mg</title>
            <description>1mg cocaine - 600mg zonisamide</description>
          </group>
          <group group_id="O4">
            <title>20mg-0mg</title>
            <description>20mg cocaine - 0mg zonisamide</description>
          </group>
          <group group_id="O5">
            <title>20mg-300mg</title>
            <description>20mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O6">
            <title>20mg-600mg</title>
            <description>20mg cocaine - 600mg zonisamide</description>
          </group>
          <group group_id="O7">
            <title>40mg-0mg</title>
            <description>40mg cocaine - 0mg zonisamide</description>
          </group>
          <group group_id="O8">
            <title>40mg-300mg</title>
            <description>40mg cocaine - 300mg zonisamide</description>
          </group>
          <group group_id="O9">
            <title>40mg-600mg</title>
            <description>40mg cocaine - 600mg zonisamide</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Value Questionnaire</title>
          <description>Street Value of Sampled Dose. After co-administration of cocaine-zonisamide, participants were asked to hypothetically estimate the value of the drug they received, if they were to purchase it on the street. The mean value (dollars) across all drug conditions is reported here.
Repeated within-subject measures ANOVA performed to observe the main effects of zonisamide dose (0, 300, and 600mg) and cocaine dose (0, 20, and 40mg), and their interaction. Only participants who received the active zonisamide medication (n=8) were included in this portion of the analysis. Additionally, all 8 subjects who received zonisamide completed both 300mg and 600mg doses.
Within-subject repeated interval during self-administration sessions. Cocaine not administered (only Zon) during Weeks 2 &amp; 4, thus no measures taken at these times</description>
          <population>Because we are interested in how co-administration cocaine-zon affects this measure, only zon participants are included (n=8). Each participant receives varying doses of zon (0, 300, 600mg) at weeks 1, 2-3, 4-5, respectively. After getting used to each zon dose, they are co-administered all 3 cocaine doses (1, 20, 40mg) during Weeks 1, 3, and 5</population>
          <units>dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="9.29" spread="7.32"/>
                    <measurement group_id="O5" value="8.50" spread="5.81"/>
                    <measurement group_id="O6" value="7.63" spread="3.54"/>
                    <measurement group_id="O7" value="16" spread="14.96"/>
                    <measurement group_id="O8" value="18.13" spread="18.31"/>
                    <measurement group_id="O9" value="9.5" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>p-value was calculated as less than 0.01. Note: this is not an attempt to indicate a threshold</p_value_desc>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Coc dose</param_type>
            <param_value>21.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Cocaine dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Zon dose</param_type>
            <param_value>0.77</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Zonisamide dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>ANOVA</method>
            <param_type>F-value for the main effect of Zon x Coc</param_type>
            <param_value>0.93</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>F-value for main effect of Zonisamide x Cocaine interaction on drug value (i.e., street value) measurement</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>39 days</time_frame>
      <desc>Reported adverse events (AEs) include participants who were randomized into the study's conditions (zonisamide/placebo), and of which were rated as being either possibly, probably, or definitely related to the study.
Although 19 participants were randomized, 9 did not complete. However, 2 of these provided sufficient data to be included in analyses. Thus, the possibility of study related AEs could only occur in 12 subjects (8 zonisamide, 4 placebo). This is the case for serious AEs, too.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zonisamide</title>
          <description>Participants administered blind capsules containing either placebo or zonisamide.
Zonisamide: Eight capsules administered daily in split doses at 22:00 and 09:00.
Cocaine Hydrochloride: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
Neurocognitive and Performance Battery: Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
Smoking Assessments: Participants answer questions about smoking and smoking behaviors are monitored.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants administered only placebo capsules containing lactose.
Placebo: capsules administered in split doses at 22:00 and 09:00.
Cocaine Hydrochloride: Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
Neurocognitive and Performance Battery: Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
Smoking Assessments: Participants answer questions about smoking and smoking behaviors are monitored.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chemistry Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Liver function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tooth Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Creatinine Elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Athlete's foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain lower extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tingling sensation in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dream abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Jittery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Annie Umbricht</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-550-1917</phone>
      <email>annieumbricht@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

